Genti in the news

November 15, 2022

GentiBio Named A BioSpace 2023 Best Places to Work

Cambridge, Mass., November 15, 2022 – GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmune, auto-inflammatory, alloimmune and allergic diseases, announced today that it has been named a BioSpace 2023 Best Place to Work.

BioSpace, the leading source for life sciences news and careers, includes 60 U.S. operating employers in its Best Places to Work list that have been recognized as the most sought-after in the industry by the life sciences community.

This is BioSpace’s second Best Places to Work list. The list demonstrates a company’s desirability in the recruitment marketplace, based on the votes and ratings of thousands of life science community members. BioSpace considers each organization’s merits with particular emphasis on culture, career growth and development opportunities, leadership, and innovation.

About Best Places to Work
Nominations for Best Places to Work were open from May to June 2022. Voting was conducted from August to September 2022. Best Places to Work includes responses from over 2,000 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organizations on attributes including: compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.

About BioSpace
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities, and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at

About GentiBio, Inc.
GentiBio, Inc. is a biotherapeutics company co-founded by pioneers in Treg biology and immunology from Seattle Children’s Research Institute, Benaroya Research Institute, and MIGAL Galilee Research Institute to develop engineered regulatory T cells programmed to treat autoimmune and inflammatory diseases. GentiBio’s Series A financing was led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, Novartis Venture Fund, and Seattle Children’s Research Institute. GentiBio’s autologous and allogeneic engineered Tregs platform integrates key technologies designed to successfully (re)establish immune tolerance and overcome major limitations in existing Treg therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that has the potential to address the fundamental cause of many diseases that result from overactivity and/or malfunctioning of the immune system. The company also has a collaboration with Bristol Myers Squibb for the development of Treg therapies for inflammatory bowel diseases. To learn more, visit

Kate Ruston
Sr. Director of People, GentiBio

Chantal Dresner
Marketing Director, BioSpace

‹ Back to News